Evaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitor.
Since phenolic glycolipid-I (PGL-I) is an unequivocal marker for Mycobacterium leprae, this antigen has been a good candidate for the serodiagnosis and monitoring of the effectiveness of leprosy chemotherapy. The present study, a continuation of an earlier report, was undertaken to estimate PGL-I antibody titers in 40 leprosy patients 3 and 6 months after starting MDT. All the leprosy groups showed significant declines in anti PGL-I reactivity after 6 months. There was a good correlation between bacteriological indices (BI) and anti PGL-I antibody levels. Thus, PGL-I based serology may be useful in monitoring the response to multidrug therapy.
Prakash
K
K
Department of Microbiology, Lady Hardinge Medical College, New Delhi, India.
Sehgal
V N
VN
Aggarwal
R
R
D000942:Antigens, Bacterial; D016903:Drug Monitoring / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D006017:Glycolipids / Q000276:immunology*; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D012698:Serologic Tests
D000942:Antigens, Bacterial; D006017:Glycolipids; C045169:phenolic glycolipid I, Mycobacterium leprae